@StickyRice:Eli Lilly, Novo could make more money on insulin despite price reductions Eli Lilly $Eli Lilly(LLY)$ and Novo Nordisk $Novo-Nordisk A/S(NVO)$ are set to make even more money off their insulin products despite price curbs by avoiding paying rebates to Medicaid. Lilly can avoid $430M annually in new Medicaid rebates and make more than $85M in additional profit per year, Bloomberg related, based on an analysis by consulting firm Veda Partners. Spencer Perlman, director of health-care research at Veda, told the news service that Novo (NVO) could avoid about $350M in new 2024 rebates on NovoLog and Levemir while adding earnings of ~$210M. Perlman noted that currently, the two companies don't make any m

@financead:Ngas prices are driven by Russia sanctions, US export capacity, and war.We like the BOIL ETF$Bloomberg Natural Gas Bull 2X ETF(BOIL)$ as a leveraged bull play on Ngas.Prices have fallen on supply chain migration away from Russia.A renewed Russian offensive is likely to start before NATO heavy armor arrives, threatening essential supplies into Spring.

@AaronJe:I am gonna buy this on Thurday. GL longs Next week we will be in the 30s.Yay me, orders filling left and right. Please Lord let the markets be up tomorrow. Amen PS Daddy needs a new RV.this will be green slow grind higher. i expect higher levels incoming. But always remember trade safe and DYODD.$Upstart Holdings, Inc.(UPST)$